Oncocyte CEO, Ronnie Andrews On Developing New Ways To Test For Lung Cancer
Watch “Ronnie Andrews On Developing New Ways To Test For Lung Cancer”, an archived episode of The Watch List originally aired 07/15/2019 on the TD Ameritrade Network.
Not just a vaccine company: How this Gaithersburg biotech CEO plans to grow the business
The Gaitherburg biotech’s CEO, not yet a year into his tenure, sees the prospect of more acquisitions or licensing deals going forward.
Positive results of a prep-free colon cancer screening device reported
Check-Cap announced positive final results from its completed post-CE approval study evaluating the efficacy and safety of the C-Scan system. “The final results from the post-CE approval study confirm the potential clinical value of the C-Scan system. The results also demonstrate an advancement in the detection of larger polyps, generally considered to have higher potential for malignant transformation,” Nadir Arber, MD, MSc, MHA, director of the Integrated Cancer Prevention Center at the Tel-Aviv Sourasky Medical Center, said in a press release.
Interview with the CEO: electroCore, Inc. (NASDAQ:ECOR)
Francis R. Amato is Chief Executive Officer of electroCore, Inc. Prior to being the Chief Executive Officer and joining electroCore in 2012, Mr. Amato spent 22 years in the pharmaceutical industry, most recently at Merck, where he served as Vice President of the Specialty Commercial Operations Group within Global Human Health.
Encore: Orchestra BioMed quickly nets another $34M for its cardiovascular pipeline
Hot on the heels of inking an international distribution deal with Terumo, Orchestra BioMed has secured $34 million in new funding for its devices aimed at high blood pressure and blocked arteries. The series B-1 raise, and its previous series B round, also provide for follow-on investments of up to $57 million in the company. The latest preferred stock financing was led by Perceptive Advisors, RTW Investments and Soleus Capital, alongside additional backing from Terumo and previous investor SternAegis Ventures.
ProQR: RNA Therapy Has Potential to Restore Vision in Patients With Usher Syndrome
Usher syndrome is an inherited retinal degeneration that affects hearing, balance, and vision. Usher syndrome caused by USH2A mutations is one of the most common causes of retinitis pigmentosa (RP) with syndromic features. Currently there is no treatment for the sensory deficits caused by Usher syndrome.
In an attempt to fill this void, QR-421a is an antisense oligonucleotide (ASO) and designed to specifically target mutations in exon 13 of the USH2A gene for the treatment of patients with RP.
Orchestra Biomed raises $34M to advance circulatory solutions
New Hope, Pa.-based Orchestra Biomed Inc. scooped up $34 million in a series B-1 preferred stock financing led by Perceive Advisors, RTW Investments and Soleus Capital. The funds will be used to advance development of the company’s Backbeat cardiac neuromodulation therapy (CNT) system, to support commitments to Orchestra’s strategic global partnership with Tokyo-based Terumo Corp. for the development and marketing of the Virtue sirolimus-eluting balloon (SEB) and to grow the company’s product pipeline and pursue future collaborations.
The Cell Therapy Discovery About To Disrupt Clinical Trials
Armon Sharei developed an interest in novel cell therapies while pursuing his PhD in chemical engineering at MIT. While pursuing that interest, he made a discovery that today is the foundation of SQZ Biotech, a cell-therapy company where he serves as CEO. Sharei discovered a new method of inserting materials into cells more effectively than anything that currently existed. His discovery is now opening doors to what researchers can force cells to do, and, as a result, what cells can do for patients.
